Updated insights on dementia‐related risk of sacubitril/valsartan: A real‐world pharmacovigilance analysis

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System

(2022) Lingqing Ding et al.   Cardiovascular Therapeutics

Anti-cancer Drugs Associated Atrial Fibrillation—An Analysis of Real-World Pharmacovigilance Data

(2022) Javaria Ahmad et al.   Frontiers in Cardiovascular Medicine

Updated Insights on Cardiac and Vascular Risks of Proton Pump Inhibitors: A Real-World Pharmacovigilance Study

(2022) Yinghong Zhai et al.   Frontiers in Cardiovascular Medicine

Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening!

(2021) Elnaz Poorgolizadeh et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions

(2020) Jason Galo et al.   American Journal of Cardiovascular Drugs

Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)

(2020) Roger J. Yu et al.   Journal of Allergy and Clinical Immunology-In Practice

Neprilysin expression and functions in development, ageing and disease

(2020) NN Nalivaeva et al.   MECHANISMS OF AGEING AND DEVELOPMENT

The Dual Role of Kinin/Kinin Receptors System in Alzheimer’s Disease

(2019) Bingyuan Ji et al.   Frontiers in Molecular Neuroscience

Angiotensin receptor/neprilysin inhibitor—a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings

(2019) Marcin Książczyk et al.   HEART FAILURE REVIEWS

Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF

(2019) Muthiah Vaduganathan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database

(2018) Amichai Perlman et al.   JOURNAL OF CARDIAC FAILURE

Practical guidance on the use of sacubitril/valsartan for heart failure

(2018) Andrew J. Sauer et al.   HEART FAILURE REVIEWS

Cognitive Impairment and Heart Failure: Systematic Review and Meta-Analysis

(2017) Jane A. Cannon et al.   JOURNAL OF CARDIAC FAILURE

The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey

(2017) Heidi A. Schoenfeld et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Trajectories of decline in cognition and daily functioning in preclinical dementia

(2016) Vincentius J.A. Verlinden et al.   Alzheimers & Dementia

Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure

(2016) Abhishek S. Chitnis et al.   American Journal of Alzheimers Disease and Other Dementias

The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects

(2016) Thomas H. Langenickel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Heart failure and risk of dementia: a Danish nationwide population-based cohort study

(2016) Kasper Adelborg et al.   EUROPEAN JOURNAL OF HEART FAILURE

Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction

(2016) Jane A. Cannon et al.   EUROPEAN JOURNAL OF HEART FAILURE

Long-term neprilysin inhibition — implications for ARNIs

(2016) Duncan J. Campbell   Nature Reviews Cardiology

A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II

(2016) F. E. Matthews et al.   Nature Communications

Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease

(2015) Robert Baranello et al.   Current Alzheimer Research

Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer’s disease

(2014) Natalia N. Nalivaeva et al.   Frontiers in Aging Neuroscience

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact

(2013) John J. V. McMurray et al.   EUROPEAN JOURNAL OF HEART FAILURE

Data Mining of the Public Version of the FDA Adverse Event Reporting System

(2013) Toshiyuki Sakaeda et al.   International Journal of Medical Sciences